Last reviewed · How we verify
Preventive antibiotic treatment- NITROFURANTOIN
At a glance
| Generic name | Preventive antibiotic treatment- NITROFURANTOIN |
|---|---|
| Sponsor | HaEmek Medical Center, Israel |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection (PHASE2)
- Prophylactic Antibiotics in Cystectomy With Diversion (EARLY_PHASE1)
- Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy (PHASE4)
- Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study (PHASE4)
- Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA (PHASE4)
- Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection (PHASE4)
- Maternal Genitourinary Infections and Adverse Perinatal Outcomes (NA)
- Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: